Page 99 - Read Online

Cendrós et al. J Transl Genet Genom 2020;4:210-20 I http://dx.doi.org/10.20517/jtgg.2020.21 Page 219

pharmacokinetics in healthy volunteers. Drug Metabol Drug Interact 2013;28:163-6.
15. van de Bilt MT, Prado CM, Ojopi EP, Sousa RT, Loch AA, et al. Cytochrome P450 genotypes are not associated with refractoriness to
antipsychotic treatment. Schizophr Res 2015;168:587-8.
16. Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Vaquero-Lorenzo C, et al; Spanish Consortium of Pharmacogenetics
Research in Schizophrenia. CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment.
Pharmacogenet Genomics 2013;23:627-30.
17. Papazisis G, Goulas A, Sarrigiannidis A, Bargiota S, Antoniadis D, et al. ABCB1 and CYP2D6 polymorphisms and treatment response of
psychotic patients in a naturalistic setting. Hum Psychopharmacol 2018;33.
18. Vijayan NN, Mathew A, Balan S, Natarajan C, Nair CM, et al. Antipsychotic drug dosage and therapeutic response in schizophrenia is
influenced by ABCB1 genotypes: a study from a south Indian perspective. Pharmacogenomics 2012;13:1119-27.
19. Kastelic M, Koprivsek J, Plesnicar BK, Serretti A, Mandelli L, et al. MDR1 gene polymorphisms and response to acute risperidone
treatment. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:387-92.
20. Suzuki Y, Tsuneyama N, Fukui N, Sugai T, Watanabe J, et al. Effect of risperidone metabolism and P-glycoprotein gene polymorphism on
QT interval in patients with schizophrenia. Pharmacogenomics J 2014;14:452-6.
21. Grădinaru R, Andreescu N, Nussbaum L, Suciu L, Puiu M. Impact of the CYP2D6 phenotype on hyperprolactinemia development as an
adverse event of treatment with atypical antipsychotic agents in pediatric patients. Ir J Med Sci 2019;188:1417-22.
22. Ivanova SA, Filipenko ML, Vyalova NM, Voronina EN, Pozhidaev IV, et al. CYP1A2 and CYP2D6 gene polymorphisms in schizophrenic
patients with neuroleptic drug-induced side effects. Bull Exp Biol Med 2016;160:687-90.
23. Hattori S, Suda A, Kishida I, Miyauchi M, Shiraishi Y, et al. Effects of ABCB1 gene polymorphisms on autonomic nervous system
activity during atypical antipsychotic treatment in schizophrenia. BMC Psychiatry 2018;18:231.
24. Arranz MJ, Gonzalez-Rodriguez A, Perez-Blanco J, Penadés R, Gutierrez B, et al. A pharmacogenetic intervention for the improvement
of the safety profile of antipsychotic treatments. Transl Psychiatry 2019;9:177.
25. Frahnert C, Rao ML, Grasmäder K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by
liquid chromatography: a simple tool for therapeutic drug monitoring. J Chromatogr B 2003;794:35-47.
26. Leucht S, Samara M, Heres S, Patel MX, Furukawa T, et al. Dose equivalents for second-generation antipsychotic drugs: the classical
mean dose method. Schizophr Bull 2015;41:1397-402.
27. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull 1987;13:261-76.
28. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, et al. A “silent” polymorphism in the MDR1 gene changes substrate
specificity. Science 2007;318:1382-3.
29. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for
psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-100.
30. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, et al. The CYP2D6 activity score: translating genotype information into a
qualitative measure of phenotype. Clin Pharmacol Ther 2008;83:234-42.
31. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, et al. Standardizing terms for clinical pharmacogenetic test
results: consensus terms from the clinical pharmacogenetics implementation consortium (CPIC). Genet Med 2017;19:215-223.
32. Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, et al. Standardizing CYP2D6 genotype to phenotype translation:
consensus recommendations from the clinical pharmacogenetics implementation consortium and dutch pharmacogenetics working group.
Clin Transl Sci 2020;13:116-24.
33. Jovanović N, Božina N, Lovrić M, Medved V, Jakovljević M, et al. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve
patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol 2010;66:1109-17.
34. Lisbeth P, Vincent H, Kristof M, Bernard S, Manuel M, et al. Genotype and co-medication dependent CYP2D6 metabolic activity: effects
on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol 2016;72:175-84.
35. Czerwensky F, Leucht S, Steimer W. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.
Ther Drug Monit 2015;37:152-60.
36. Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, et al. ABCB1 and cytochrome P450 polymorphisms: clinical
pharmacogenetics of clozapine. J Clin Psychopharmacol 2009;29:319-26.
37. Tóth K, Csukly G, Sirok D, Belic A, Kiss Á, et al. Potential role of patients’ CYP3A-status in clozapine pharmacokinetics. Int J
Neuropsychopharmacol 2017;20:529-37.
38. Huang HC, Lua AC, Wu LS, Wu BJ, Lee SM, et al. Cigarette smoking has a differential effect on the plasma level of clozapine in
Taiwanese schizophrenic patients associated with the CYP1A2 gene-163A/C single nucleotide polymorphism. Psychiatr Genet
2016;26:172-7.
39. Rafaniello C, Sessa M, Bernardi FF, Pozzi M, Cheli S, et al. The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6
polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions. Pharmacogenomics
J 2018;18:422-30.
40. Nikisch G, Baumann P, Oneda B, Kiessling B, Weisser H, et al. Cytochrome P450 and ABCB1 genetics: association with quetiapine and
norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot
study. J Psychopharmacol 2011;25:896-907.
41. Piatkov I, Caetano D, Assur Y, Lau SL, Coelho M, ET AL. CYP2C19*17 protects against metabolic complications of clozapine treatment.
World J Biol Psychiatry 2017;18:521-7.
42. Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC, et al. Cytochrome P-450 activities in human and rat brain microsomes.